The role of NFAT in the pathogenesis and targeted therapy of hematological malignancies

Eur J Pharmacol. 2022 Apr 15:921:174889. doi: 10.1016/j.ejphar.2022.174889. Epub 2022 Mar 12.

Abstract

The nuclear factor of activated T cells (NFAT) family is well known for the survival of hemopoietic cells and plays an important role in the immune response. In recent decades, NFAT alteration was discovered in hematological malignancies, suggesting that targeted NFAT therapy may be a promising strategy for the treatment of hematological malignancies. In this review, we present an overview of the NFAT signaling pathway in lymphocytes as well as aberrant NFAT in hematological malignancies. Moreover, therapeutically targeting NFAT in hematological malignancies is also discussed in this review.

Keywords: Hematological malignancies; Nuclear factor of activated T cells; T cells immunity; Target therapy.

Publication types

  • Review

MeSH terms

  • Cell Nucleus / metabolism
  • Hematologic Neoplasms* / drug therapy
  • Humans
  • NFATC Transcription Factors / metabolism
  • Signal Transduction
  • T-Lymphocytes*

Substances

  • NFATC Transcription Factors